KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Interest & Investment Income: 2009

Historic Interest & Investment Income for Halozyme Therapeutics (HALO) over the last 1 years, with Dec 2009 value amounting to $11,346.

  • Halozyme Therapeutics' Interest & Investment Income was N/A to $11,346 in Q4 2009 from the same period last year, while for Dec 2009 it was $97,737, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2016, which is 214.22% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Interest & Investment Income of $11,346 as of Q4 2009, which was down 61.30% from $29,318 recorded in Q3 2009.
  • In the past 5 years, Halozyme Therapeutics' Interest & Investment Income registered a high of $33,378 during Q1 2009, and its lowest value of $11,346 during Q4 2009.
  • Its 1-year average for Interest & Investment Income is $24,434, with a median of $26,506 in 2009.